The best guess approach to phase I trial designROSA, Daniela D; HARRIS, John; JAYSON, Gordon C et al.Journal of clinical oncology. 2006, Vol 24, Num 1, pp 206-208, issn 0732-183X, 3 p.Article

TCNU: a ray of hope for designer nitrosoureas?WORKMAN, P.European journal of cancer & clinical oncology. 1987, Vol 23, Num 12, pp 1823-1828, issn 0277-5379Article

Multi-Institutional Phase I Trials of Anticancer AgentsDOWLATI, Afshin; MANDA, Sudhir; GIBBONS, Joseph et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 1926-1931, issn 0732-183X, 6 p.Article

What Oncologists Believe They Said and What Patients Believe They Heard: An Analysis of Phase I Trial DiscussionsJENKINS, Valerie; SOLIS-TRAPALA, Ivonne; LANGRIDGE, Carolyn et al.Journal of clinical oncology. 2011, Vol 29, Num 1, pp 61-68, issn 0732-183X, 8 p.Article

Translation of innovative designs into phase I trialsROGATKO, André; SCHOENECK, David; JONAS, William et al.Journal of clinical oncology. 2007, Vol 25, Num 31, pp 4982-4986, issn 0732-183X, 5 p.Article

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerGOETZ, Matthew P; TOFT, David; SALAZAAR, Sandra et al.Journal of clinical oncology. 2005, Vol 23, Num 6, pp 1078-1087, issn 0732-183X, 10 p.Article

Complementary and alternative medicine use by patients enrolled onto phase I clinical trialsDY, Grace K; BEKELE, Lishan; HANSON, Lorelei J et al.Journal of clinical oncology. 2004, Vol 22, Num 23, pp 4758-4763, issn 0732-183X, 6 p.Article

Essai phase I de la suricloneMURASAKI, M; OKAMOTO, K; ISHII, Y et al.Yakuri to chiryo. 1987, Vol 15, Num 5, pp 193-258, issn 0386-3603Article

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center InitiativeTSIMBERIDOU, Apostolia-Maria; ISKANDER, Nancy G; YANG YE et al.Clinical cancer research (Print). 2012, Vol 18, Num 22, pp 6373-6383, issn 1078-0432, 11 p.Article

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonistCINES, Douglas B; JENKINS, Julian M; WILLIAMS, Daphne et al.Blood. 2007, Vol 109, Num 11, issn 0006-4971, 4591-4592, 4739-4741 [5 p.]Article

A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agentRADEMAKER-LAKHAI, Jeany M; VAN DEN BONGARD, Desiree; PLUIM, Dick et al.Clinical cancer research. 2004, Vol 10, Num 11, pp 3717-3727, issn 1078-0432, 11 p.Article

Individualized patient dosing in phase I clinical trials: The role of Escalation with Overdose control in PNU-214936CHENG, Jonathan D; BABB, James S; WEINER, Louis M et al.Journal of clinical oncology. 2004, Vol 22, Num 4, pp 602-609, issn 0732-183X, 8 p.Article

Adverse events in phase one studies : a study in 430 healthy volunteersSIBILLE, M; DEIGAT, N; OLAGNIER, V et al.European journal of clinical pharmacology. 1992, Vol 42, Num 4, pp 389-393, issn 0031-6970Article

Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641)HAINSWORTH, J. D; HANDE, K. R; SATTERLEE, W. G et al.Cancer research (Baltimore). 1989, Vol 49, Num 18, pp 5217-5220, issn 0008-5472, 4 p.Article

AQUAVAN® injection, a water-soluble prodrug ofpropofol, as a bolus injection: A phase I dose-escalation comparison with DIPRIVAN® (Part 2) : Pharmacodynamics and safetySTRUYS, Michel M. R. F; VANLUCHENE, Ann L. G; GIBIANSKY, Ekaterina et al.Anesthesiology (Philadelphia). 2005, Vol 103, Num 4, pp 730-743, issn 0003-3022, 14 p.Article

Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 daysYAMADA, Yasuhide; YAMAMOTO, Noboru; SHIMOYAMA, Tatsu et al.Cancer science. 2005, Vol 96, Num 10, pp 721-728, issn 1347-9032, 8 p.Article

Les essais cliniques de phase 1 = Phase 1 clinical trialsJAILLON, P.La Presse médicale (1983). 2001, Vol 30, Num 19, pp 952-955, issn 0755-4982Article

Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerationsNEWELL, D. R.British journal of cancer. 1990, Vol 61, Num 2, pp 189-191, issn 0007-0920Article

Phase I research and the meaning of direct benefitROSS, Lainie.The Journal of pediatrics. 2006, Vol 149, Num 1, issn 0022-3476, S20-S24, SUP1Conference Paper

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)BISSETT, D; CASSIDY, J; SPINELLI, R et al.British journal of cancer. 2004, Vol 91, Num 1, pp 50-55, issn 0007-0920, 6 p.Article

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsMANI, Sridhar; MCDAID, Hayley; HORWITZ, Susan Band et al.Clinical cancer research. 2004, Vol 10, Num 4, pp 1289-1298, issn 1078-0432, 10 p.Article

Pharmaco-electroencephalography in phase ILUTHRINGER, R; BOEIJINGA, P. H.Methods and findings in experimental and clinical pharmacology. 2002, Vol 24, issn 0379-0355, p. 95, SUPDConference Paper

Proposing phase I studies : Patients', relatives', nurses' and specialists' perceptionsTOMAMICHEL, M; JAIME, H; DEGRATE, A et al.Annals of oncology. 2000, Vol 11, Num 3, pp 289-294, issn 0923-7534Article

Umgang mit Unerwünschten Ereignissen in Phase-I-Prüfungen = Dealing with Adverse Events in Phase I TrialsHEGER-MAHN, D; MAHLER, M; HERMANN, R et al.Arzneimittel-Forschung. 1995, Vol 45, Num 3, pp 331-336, issn 0004-4172Article

Pharmacokinetic characterization of mitonafide in manBRODE, E; POVEDA VELASCO, A; DIAZ-RUBIO, E et al.Methods and findings in experimental and clinical pharmacology. 1992, Vol 14, Num 2, pp 131-140, issn 0379-0355Article